Author details

Full Name

Benjamin L Ebert

Affiliation

ORCID

Career Start Year

1994

Papers

295

H Index

Expertise

CM4AI Collaborator

PMID	Paper Title	Journal Title	Published Year
37095859	The human E3 ligase RNF185 is a regulator of the SARS-CoV-2 envelope protein.	iScience	2023
37756546	Runx1-R188Q germ line mutation induces inflammation and predisposition to hematologic malignancies in mice.	Blood Adv	2023
37595362	PPM1D modulates hematopoietic cell fitness and response to DNA damage and is a therapeutic target in myeloid malignancy.	Blood	2023
37909388	Somatic TET2 Mutations are Associated with Giant Cell Arteritis.		2023
37725576	Integration of Genomic Sequencing Drives Therapeutic Targeting of PDGFRA in T-Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma.	Clin Cancer Res	2023
37478846	UBR5 forms ligand-dependent complexes on chromatin to regulate nuclear hormone receptor stability.	Mol Cell	2023
37345823	Birth Weight Is Associated With Clonal Hematopoiesis of Indeterminate Potential and Cardiovascular Outcomes in Adulthood.		2023
36652671	A practical approach to curate clonal hematopoiesis of indeterminate potential in human genetic data sets.	Blood	2023
37339579	Epichaperome inhibition targets TP53-mutant AML and AML stem/progenitor cells.		2023
36824856	Template-assisted covalent modification of DCAF16 underlies activity of BRD4 molecular glue degraders.	bioRxiv	2023
36949957	<i>TP53-</i>mediated clonal hematopoiesis confers increased risk for incident atherosclerotic disease.	Nat Cardiovasc Res	2023
37391485	RUNX1 mutations mitigate quiescence to promote transformation of hematopoietic progenitors in Fanconi anemia.		2023
37197843	Clonal Hematopoiesis of Indeterminate Potential Predicts Adverse Outcomes in Patients With Atherosclerotic Cardiovascular Disease.		2023
37071471	Obesity-induced inflammation exacerbates clonal hematopoiesis.	J Clin Invest	2023
36945568	A molecular glue approach to control the half-life of CRISPR-based technologies.	bioRxiv	2023
36480766	Clonal Hematopoiesis and Risk of Incident Lung Cancer.	J Clin Oncol	2023
36941354	Clonal haematopoiesis and dysregulation of the immune system.		2023
37237081	Genome-scale functional genomics identify genes preferentially essential for multiple myeloma cells compared to other neoplasias.	Nat Cancer	2023
37225367	Increased Risk ofÂ Thoracic Aortic Aneurysms With JAK2Â V617F.	J Am Coll Cardiol	2023
37498674	Genetic modification of inflammation- and clonal hematopoiesis-associated cardiovascular risk.	J Clin Invest	2023
37483562	Prediction of risk for myeloid malignancy in clonal hematopoiesis.	NEJM Evid	2023
34875037	Age-related diseases of inflammation in myelodysplastic syndrome and chronic myelomonocytic leukemia.	Blood	2022
35773251	Allosteric inhibition of PPM1D serine/threonine phosphatase via an altered conformational state.	Nat Commun	2022
35714308	TET2-mutant clonal hematopoiesis and risk of gout.	Blood	2022
36108743	A STUB1 ubiquitin ligase/CHIC2 protein complex negatively regulates the IL-3, IL-5, and GM-CSF cytokine receptor common Î² chain (CSF2RB) protein stability.	Journal of Biological Chemistry	2022
35654360	Clonal Hematopoiesis and Mosaicism Revealed by a Multi-Tissue Analysis of Constitutional TP53 Status.	Cancer Epidemiol Biomarkers Prev	2022
35767897	International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data.	Blood	2022
35763353	Degradation of GSPT1 causes TP53-independent cell death in leukemia while sparing normal hematopoietic stem cells.	J Clin Invest	2022
35650394	Blood's life history traced through genomic scars.	Nature	2022
35512188	Lenalidomide promotes the development of TP53-mutated therapy-related myeloid neoplasms.	Blood	2022
36097025	Clonal hematopoiesis of indeterminate potential, DNA methylation, and risk for coronary artery disease.	Nat Commun	2022
36096050	Clonal hematopoiesis of indeterminate potential andÂ risk of death from COVID-19.	Blood	2022
35822488	Targeting stem cells in myelodysplastic syndromes and acute myeloid leukemia.	Journal of Internal Medicine	2022
35508625	Genetics of smoking and risk of clonal hematopoiesis.	Sci Rep	2022
35385311	Mendelian randomization supports bidirectional causality between telomere length and clonal hematopoiesis of indeterminate potential.	Sci Adv	2022
36151141	Activity of menin inhibitor ziftomenib (KO-539) as monotherapy or in combinations against AML cells with MLL1 rearrangement or mutant NPM1.	Leukemia	2022
35492812	Leukemia and Heart Disease: Lessons at the Intersection of the Most Feared CHIP Outcomes.	JACC: CardioOncology	2022
36130297	Genomic profiling for clinical decision making inÂ myeloid neoplasms and acute leukemia.	Blood	2022
35797463	Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN.	Blood	2022
35362549	Evolution of severe (transfusion-dependent) anaemia in myelodysplastic syndromes with 5q deletion is characterized by a macrophage-associated failure of the eythropoietic niche.	Br J Haematol	2022
36129839	Patient perspectives on testing for clonal hematopoiesis ofÂ indeterminate potential.	Blood Adv	2022
36264590	Clonal hematopoiesis transcending species barriers.	Blood	2022
34743536	Clonal Hematopoiesis Is Associated With Higher Risk of Stroke.	Stroke	2022
34677878	Congenital X-linked neutropenia with myelodysplasia and somatic tetraploidy due to a germline mutation in SEPT6.	Am J Hematol	2022
34855941	Association of clonal hematopoiesis with chronic obstructive pulmonary disease.	Blood	2022
35256801	High burden of clonal hematopoiesis in first responders exposed to the World Trade Center disaster.	Nat Med	2022
35026842	TP53 mutations confer resistance to hypomethylating agents and BCL-2 inhibition in myeloid neoplasms.	Blood advances	2022
34965125	Development of PDE6D and CK1Î± Degraders through Chemical Derivatization of FPFT-2216.	J Med Chem	2022
34780598	An improved index for diagnosis and mortality prediction in malignancy-associated hemophagocytic lymphohistiocytosis.	Blood	2022
35017466	Effective Menin inhibitor-based combinations against AML with MLL rearrangement or NPM1 mutation (NPM1c).	Blood Cancer J	2022